Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "atorvastatin" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-9 z 9
    Tytuł:
    Influence of some statins on bacteria and actinomyces
    Wpływ niektórych statyn na bakterie i promieniowce
    Autorzy:
    Targonski, R.
    Kucharski, J.
    Wyszkowska, J.
    Powiązania:
    https://bibliotekanauki.pl/articles/14254.pdf
    Data publikacji:
    2006
    Wydawca:
    Uniwersytet Warmińsko-Mazurski w Olsztynie / Polskie Towarzystwo Magnezologiczne im. Prof. Juliana Aleksandrowicza
    Tematy:
    atorvastatin
    bacteria
    statin
    simvastatin
    fluvastatin
    Bacillus subtilis
    Bacillus cereus
    Proteus vulgaris
    Pseudomonas fluorescens
    Escherichia coli
    actinomycete
    Opis:
    In an in uitro experiment the effect of three statins (atorvastatin [Sortis], simvastatin [Zocor], fluvastatin [Lescol]) on the growth of 5 bacterial strains Bacillus subtilis, Bacillus cereus, Proteus vulgaris, Pseudomonas fluorescens, Escherichia coli and 4 saprophytic actinomycetes Streptomyces longisporoflavus, Streptomyces intermedius, Streptomyces odoriver, Streptomyces viridis was tested. The experiments were carried out on solidified substrata with microorganisms covered with filter paper rings soaked with aqueous solution of every tested statin used in different concentrations. It was found that examined substances can inhibit the growth of certain saprophytic microorganisms. Fluvastatin rather than simvastatin or atorvastatin produces stronger effect on bacteria and actinomycetes.
    W doświadczeniu in vitro badano wpływ trzech statyn (atorwastatyny [Sortis], simwastatyny [Zocor], fluwastatyny [Lescol]) na rozwój 5 szczepów bakterii: Bacillus subtilis, Bacillus cereus, Proteus vulgaris, Pseudomonas fluorescens, Escherichia coli oraz 4 saprofitycznych promieniowców: Streptomyces longisporoflavus, Streptomyces intermedius, Streptomyces odoriver, Streptomyces viridis. Doświadczenia prowadzono na zestalonych podłożach, przy czym mikroorganizmy przykrywano krążkami papieru filtrującego, nasączonymi wodnym roztworem poszczególnych statyn w różnych stężeniach. Stwierdzono, że badane substancje mogą ograniczać rozwój pewnych mikroorganizmów saprofitycznych. Fluwastatyna miała silniejszy wpływ hamujący na bakterie i promienowce niż simwastatyna lub atorwastatyna.
    Źródło:
    Journal of Elementology; 2006, 11, 4
    1644-2296
    Pojawia się w:
    Journal of Elementology
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study
    Autorzy:
    Renke, Marcin
    Tylicki, Leszek
    Rutkowski, Przemysław
    Neuwelt, Alexander
    Larczyński, Wojciech
    Ziętkiewicz, Marcin
    Aleksandrowicz, Ewa
    Łysiak-Szydłowska, Wiesława
    Rutkowski, Bolesław
    Powiązania:
    https://bibliotekanauki.pl/articles/1040322.pdf
    Data publikacji:
    2010
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    proteinuria
    kidney
    tubular injury
    chronic kidney disease
    Atorvastatin
    Opis:
    Background. There is evidence that dyslipidemia is associated with chronic kidney disease (CKD) and it has been implicated in the progression of renal damage. Optimal management of dyslipidemia should therefore lead to renal benefits. A number of experimental models demonstrate a beneficial effect of statins in ameliorating renal damage. However, the exact mechanism by which statins protect against renal damage remains unclear. Methods. In a placebo-controlled, randomized, cross-over study we evaluated the influence of atorvastatin (ATO) 40 mg/day added to the renin-angiotensin-aldosterone systeme (RAAS) blockade on proteinuria and surrogate biomarkers of tubular damage or injury in 14 non-diabetic patients with proteinuria (0.4-1.8 g per 24 h) with normal or declined kidney function (eGFR 55-153 ml/min). In the eight-week run-in period, therapy using angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin II subtype 1 receptor antagonists (ARB) was adjusted to achieve a blood pressure below 130/80 mm Hg. Next, patients were randomly assigned to one of two treatment sequences: ATO/washout/placebo or placebo/washout/ATO. Clinical evaluation and laboratory tests were performed at the randomization point and after each period of the study. The primary end point of this study was a change in proteinuria measured as 24-h urine protein excretion (DPE). Secondary end points included urine N-acetyl-β-d-glucosaminidase (NAG) and α1-microglobulin (α1m) excretion. Results. The ATO therapy significantly reduced urine excretion of α1m (p=0.033) and NAG (p=0.038) as compared to placebo. There were no differences in proteinuria, blood pressure, eGFR and serum creatinine between the ATO and placebo groups. Conclusion. Atorvastatin treatment is safe and improves biomarkers of tubular damage or injury in non-diabetic patients with CKD.
    Źródło:
    Acta Biochimica Polonica; 2010, 57, 4; 547-552
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Nowoczesna farmakoterapia kardiologiczna w świetle nowych wytycznych Europejskiego Towarzystwa Kardiologicznego z 2013 roku
    Novel cardiovascular therapy according to 2013 guidelines of the European Society of Cardiology
    Autorzy:
    Szymański, Filip M.
    Powiązania:
    https://bibliotekanauki.pl/articles/1032989.pdf
    Data publikacji:
    2013
    Wydawca:
    Medical Communications
    Tematy:
    atorvastatin
    atorwastatyna
    guidelines
    kwas acetylosalicylowy European Society of Cardiology
    ramipril
    rosuvastatin
    europejskie towarzystwo kardiologiczne
    wytyczne
    telmisartan
    kwas acetylosalicylowy
    rosuwastatyna
    Opis:
    This year, the European Society of Cardiology (ESC) has published new guidelines on the diagnosis and management of arterial hypertension, management of patients with stable coronary artery disease and guidelines on approach to cardiovascular disease in patients with diabetes and pre-diabetes. The incidence of all of these disorders in the general population is very high. In everyday clinical practice, physicians, regardless their specialties, very often face patients with arterial hypertension, diabetes or coronary artery disease. To treat patients in accordance with the latest recommendations, clinicians must constantly learn and expand their knowledge. In the context of the publication of the new guidelines it is particularly important to familiarize yourself with the newly introduced rules on pharmacotherapy in relation to newest findings published in recent years. In this field changes are the most dynamic and with a very high degree of influence on the treatment of patients. Some of pharmaceutical groups used in cardiology are gaining importance, others are slowly being replaced. Position of drug classes such as angiotensin converting enzyme inhibitors, angiotensin receptor blockers, statins or aspirin in the treatment and prevention of cardiovascular events, in the current guidelines has been strengthened. However, in the case of these classes of drugs very important is the choice of specific substance, which will meet the expectations of both the effectiveness and safety in therapy. Present paper, in addition to summarizing the ESC most recent guidelines, demonstrates scientific evidence for the clinical efficacy of substances such as ramipril, telmisartan, atorvastatin or rosuvastatin in patients with diseases of the cardiovascular system.
    W bieżącym roku Europejskie Towarzystwo Kardiologiczne (European Society of Cardiology, ESC) opublikowało nowe wytyczne dotyczące diagnostyki i leczenia nadciśnienia tętniczego, postępowania u chorych ze stabilną chorobą wieńcową oraz wytyczne dotyczące chorób układu sercowo-naczyniowego w grupie pacjentów z cukrzycą. Częstość występowania wszystkich tych schorzeń w populacji ogólnej jest bardzo wysoka. W codziennej praktyce klinicznej lekarze, niezależnie od wykonywanej specjalizacji, bardzo często spotykają się z pacjentami z nadciśnieniem tętniczym, cukrzycą czy chorobą wieńcową. Aby leczyć pacjentów zgodnie z najnowszymi zaleceniami, lekarze praktycy muszą stale pogłębiać swoją wiedzę. W kontekście publikacji nowych wytycznych szczególnie istotne jest zapoznanie się z wprowadzanymi zasadami dotyczącymi farmakoterapii – właśnie w stosunku do leczenia farmakologicznego obserwowane w ostatnich latach zmiany są najbardziej dynamiczne i w bardzo wysokim stopniu wpływają na sposób postępowania z pacjentami. Niektóre ze stosowanych w kardiologii grup farmaceutycznych zyskują na znaczeniu, inne powoli zastępowane są nowymi substancjami. W obecnych wytycznych pozycja inhibitorów konwertazy angiotensyny, blokerów receptora angiotensynowego, statyn oraz kwasu acetylosalicylowego w leczeniu oraz prewencji incydentów sercowo-naczyniowych została umocniona. Jednak w przypadku wymienionych grup leków bardzo istotny jest wybór substancji, która będzie spełniać oczekiwania dotyczące zarówno skuteczności działania, jak i bezpieczeństwa terapii. Poniższa praca, poza podsumowaniem najnowszych wytycznych ESC, pokazuje dowody naukowe potwierdzające skuteczność kliniczną takich substancji, jak ramipril, telmisartan, atorwastatyna czy rosuwastatyna, u pacjentów z chorobami układu sercowo-naczyniowego.
    Źródło:
    Pediatria i Medycyna Rodzinna; 2013, 9, 3; 232-236
    1734-1531
    2451-0742
    Pojawia się w:
    Pediatria i Medycyna Rodzinna
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The influence of elastin degradation products, glucose and atorvastatin on metalloproteinase-1, -2, -9 and tissue inhibitor of metalloproteinases-1, -2, -3 expression in human retinal pigment epithelial cells
    Autorzy:
    Dorecka, Mariola
    Francuz, Tomasz
    Garczorz, Wojciech
    Siemianowicz, Krzysztof
    Romaniuk, Wanda
    Powiązania:
    https://bibliotekanauki.pl/articles/1039285.pdf
    Data publikacji:
    2014
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    metalloproteinase
    TIMP
    atorvastatin
    HRPE
    Opis:
    Purpose: Hyperglycemia and increased concentrations of elastin degradation products (EDPs) are common findings in patients with diabetes, atherosclerosis and hypertension. The aim of this study was to assess the influence of high glucose, EDPs and atorvastatin on MMP-1, MMP-2, MMP-9 and TIMP1-3 gene expression in human retinal pigment epithelial cells (HRPE) in vitro. Method: HRPE were cultured for 24 hours with the substances being tested (glucose, EDPs), alone or in combination. Additionally, the cells were treated with atorvastatin in two different concentrations (1 or 10 μM). After incubation, total cellular RNA was extracted and used for gene expression evaluation. Gene expression was measured using the real-time RT-PCR technique. Results: Glucose, EDPs and atorvastatin had no impact on TIMP-1 and TIMP-3 expression. HRPE cells treated with glucose or EDPs with the addition of atorvastatin had a statistically significant decrease of TIMP-2 expression; glucose alone decreased MMP-1 expression. Atorvastatin decreased expression of all assessed genes, except TIMP-1 and TIMP-3 in a dose-dependent manner. Conclusions: Our results confirm the importance of MMPs and TIMPs in retinal vascular biology. Atorvastatin-induced MMPs gene expression can deeply affect extracellular matrix turnover, which may play an important role in the progression of ocular diseases.
    Źródło:
    Acta Biochimica Polonica; 2014, 61, 2; 265-270
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Interindividual variability of atorvastatin treatment influence on the MPO gene expression in patients after acute myocardial infarction
    Autorzy:
    Sygitowicz, Grażyna
    Maciejak, Agata
    Piniewska-Juraszek, Joanna
    Pawlak, Maciej
    Góra, Monika
    Burzyńska, Beata
    Dłużniewski, Mirosław
    Opolski, Grzegorz
    Sitkiewicz, Dariusz
    Powiązania:
    https://bibliotekanauki.pl/articles/1038846.pdf
    Data publikacji:
    2016
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    MPO gene expression
    myeloperoxidase
    C-reactive protein
    atorvastatin
    acute myocardial infarction
    Opis:
    Myeloperoxidase (MPO) and C-reactive protein (CRP) may play critical roles in generation of oxidative stress and the development of the systemic inflammatory response. The aim of the study was to determine the effect of atorvastatin therapy on the MPO gene expression and its plasma level in relation to lipids level lowering and an anti-inflammatory response in patients after acute myocardial infarction. The research material was represented by 112 samples. Thirty-eight patients with first AMI receiving atorvastatin therapy (40 mg/day) and followed up for one month were involved in the study. The relative MPO gene expression in peripheral blood mononuclear cells (PBMCs) was examined using RT-qPCR in 38 patients before-, 38 patients after-therapy and in 36 patients as the control group. The plasma concentrations of MPO and serum concentrations of biochemical parameters were determined using commercially available diagnostic tests. After one month of atorvastatin therapy, in 60.5% patients a decrease of MPO gene expression, whereas in 39.5% patients an increase, was observed. The plasma MPO levels behaved in the same way as the MPO gene expression. However, the serum lipids and CRP concentrations were significantly lower after one month of atorvastatin therapy in both groups of patients - with decreased and increased MPO gene expression. Atorvastatin exhibited a different effect on MPO gene expression and its plasma level. Short-term atorvastatin therapy resulted in lipid lowering and anti-inflammatory activity in patients after AMI, independently of its effect on MPO gene expression. The molecular mechanisms of this phenomenon are not yet defined and require further research.
    Źródło:
    Acta Biochimica Polonica; 2016, 63, 1; 89-95
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Atorvastatin adsorption studies on chitosans in an in vitro pharmaceutical model
    Autorzy:
    Meler, Jan
    Grimling, Bożena
    Szcześniak, Maria
    Karolewicz, Bożena
    Biernat, Paweł
    Powiązania:
    https://bibliotekanauki.pl/articles/1034415.pdf
    Data publikacji:
    2018
    Wydawca:
    Sieć Badawcza Łukasiewicz - Polskie Towarzystwo Chitynowe
    Tematy:
    Atorvastatin
    adsorption
    chitosan
    Opis:
    During the pharmacological therapy of specific diseases, drugs are used which, with other preparations or foods, can create connections, in many cases changing or even blocking their action. On the other hand, the use of unsuitable polymers as excipients may result in drug-polymer incompatibilities. Interactions consisting mainly of the occurrence of the adsorption phenomenon and on the formation of complex bonds that reduce the effect of the drugs are of particular importance. The aim of the study was to investigate whether the active substance atorvastatin is incompatible with dietary supplements containing chitosan. The phenomenon of the adsorption of the drug was examined using a static model of a pharmaceutical gastrointestinal tract, in the concentration range generally ingested in a single dose. Measurement results of the amount of bound drug were used to determine the average percentage of adsorbed drug dose. The results of the study prove that the anticholinesterase drug is adsorbed on chitosan in the pH ranges used, and that the binding capacity depends on the chitosan variety, which indirectly affects the reaction of the environment. It was observed that the average size of sorption depending on the chitosan variety ranged from 38% to 86%. The fact that the lowest value of adsorption was at pH 6.4 can be explained by the chemical properties of chitosan, which shows a charge only at pH >6.7. Under such conditions, the phenomenon of electrostatic adsorption may occur in relation to the healing substances of weak acids. At a pH above 7.6, corresponding to the intestinal fluid-filled intestine, the mean sorption for the highest dose of chitosan was from 38–86%. The increase in the adsorbed amount of anticholinesterase drugs on the polymer along with the increase in pH from 7.6 to 8.0 can be explained by the chitosan swelling properties, which increase with an increase in the pH. As a result, the specific surface area of the polymer and its sorption capacity increase. Based on the above considerations, it can be concluded that there is an antagonistic interaction between the drug and the polymer studied, which involves the adsorption of a drug from this group on the polymer (chitosan) and a decrease in its bioavailability
    Źródło:
    Progress on Chemistry and Application of Chitin and its Derivatives; 2018, 23; 140-148
    1896-5644
    Pojawia się w:
    Progress on Chemistry and Application of Chitin and its Derivatives
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Hypolipidemic action of rutin on triton WR-1339-induced hyperlipidemia in rats
    Autorzy:
    Livingston Raja, N.R.
    Nair, A.R.
    Senthilpandian, S.
    Ravi, V.
    Powiązania:
    https://bibliotekanauki.pl/articles/2098294.pdf
    Data publikacji:
    2020
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    rutin
    flavonoids
    triglyceride
    atorvastatin
    Triton WR-1339
    hyperlipidemia
    cholesterol
    rat
    Opis:
    Introduction and objective. Hyperlipidemia is considered as a serious communal problem in developed countries, caused by an excess level of cholesterol in blood circulation. It leads to chronic illness and even death in human beings. As the currently available drugs cause unexpected side-effect, the aim of this study is to concentrate on naturally occurring flavonoids which can potentially provide defensive and therapeutic effects in atherosclerosis diseases, and investigate the hypolipidemic effect of rutin on Triton WR-1339 triggered hyperlipidemia in a rat blood sample. Materials and method. Rats were randomly prearranged into five different groups of five rats each. Group-I was the non-disease control and administered normal saline. Group-II was the atherogenic control, administered Triton WR 1339 (200 mg/kg BW). Group-III was standard and received Atorvastatin. The last two groups (IV, V) were tested (I&II) by administering administered Rutin (40 mg/kg, 80 mg/kg) orally. The test material (I&II) and the standard drug were administered for seven days. After the last dose, blood samples were collected and the lipid levels estimated in the blood samples. Results. Rats treated with rutin flavonoid at a dose of 40 mg/kg & 80mg/kg exhibited a reduction in Total Cholesterol, Triglycerides, Low Density Lipoprotein (LDL) and Very Low Density Lipoprotein (VLDL). Rutin also increases the High Density Lipoprotein (HDL), compared with control rats. Rutin treated rats exhibited dose-dependent hypolipidemic activity. The protection percentage of rutin against hyperlipidemia was observed as 41.89%, 55.57% whereas the atorvastatin treated group protection was observed at 60.63%. Conclusions. The results of the study revealed that rutin showed a significant hypolipidemic effectiveness on Triton WR- 1339 induced hyperlipidemia in rats.
    Źródło:
    Journal of Pre-Clinical and Clinical Research; 2021, 15, 2; 51-55
    1898-2395
    Pojawia się w:
    Journal of Pre-Clinical and Clinical Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Atorwastatyna i ezetymib – skuteczne połączenie w terapii dyslipidemii
    Atorvastatin and ezetimibe – effective combination therapy for dyslipidemia
    Autorzy:
    Pęksa, Jan W.
    Powiązania:
    https://bibliotekanauki.pl/articles/2138887.pdf
    Data publikacji:
    2022-04-01
    Wydawca:
    Wydawnictwo Naukowe Medyk sp. z o.o.
    Tematy:
    atorvastatin
    ezetimibe
    cardiovascular risk
    chronic coronary syndromes
    combination therapy
    atorwastatyna
    ezetymib
    ryzyko sercowo-naczyniowe
    przewlekłe zespoły wieńcowe
    terapia złożona
    Opis:
    A good therapeutic option in hypercholesterolemia is the use of combination preparations containing an HMG-CoA reductase inhibitor, such as atorvastatin, and a drug that selectively inhibits the absorption of holesterol and plant sterol derivatives from the gut - ezetimibe - in a single tablet. Such treatment can be implemented in adults with primary hypercholesterolemia, familial hypercholesterolemia or mixed hyperlipidemia, which is already controlled with atorvastatin and ezetimibe as separate preparations, at the same doses as in the combination preparation. The preparation is administered 1x /day at any time, day. It is mostly a safe drug and well tolerated by patients. Possible side effects are mainly due to possible side effects of statins.
    Źródło:
    Gabinet Prywatny; 2022, 284, 04; 7-12
    2353-8600
    Pojawia się w:
    Gabinet Prywatny
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Połączenie atorwastatyny i ezetymibu w terapii hipercholesterolemii
    Autorzy:
    Pęksa, Jan
    Powiązania:
    https://bibliotekanauki.pl/articles/2080187.pdf
    Data publikacji:
    2022-06-22
    Wydawca:
    Wydawnictwo Naukowe Medyk sp. z o.o.
    Tematy:
    atorvastatin
    ezetimibe
    cardiovascular risk
    chronic coronary syndromes
    atorwastatyna
    ezetymib
    ryzyko sercowo-naczyniowe
    przewlekłe zespoły wieńcowe
    Opis:
    Cardiovascular (CV) diseases are still the leading cause of death in Poland. In treatment of hypercholesterolemia, HMG-CoA reductase inhibitors (statins) are the first-line drugs with proven beneficial effect on patient prognosis. These drugs include one of the two potent statins, atorvastatin. If the target level of LDL cholesterol is not achieved despite lifestyle changes and statin therapy, a drug with a different mechanism of action, e.g. ezetimibe, is added to the treatment. In this way a greater hypolipemic effect is achieved. Single pill combinations (SPC) containing two active substances in one tablet are a good choice. Indications for therapy with SPC preparations with statins and ezetimibe include therapy for primary hypercholesterolemia, mixed hyperlipidemia, heterozygous and homozygous familial hypercholesterolemia, and prevention of CV events in patients at increased risk for these incidents. SPC drug is used to control hypercholesterolemia with atorvastatin and ezetimibe as separate formulations, at the same doses as in the combination formulation. SPC formulations containing 10 mg of ezetimibe in combination with 10 or, 20, or 40 or 80 mg of atorvastatin are available on the Polish pharmaceutical market.
    Źródło:
    Gabinet Prywatny; 2022, 282, 03; 5-13
    2353-8600
    Pojawia się w:
    Gabinet Prywatny
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-9 z 9

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies